CompanyImmunoPrecise Antibodies Ltd.
Canada
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company's experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise's full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development.
Private/Public:
public
Phone:+1-250-483-0308
Fax:+1-250-483-0309
Email:[email protected]
Website:https://immunoprecise.com
Address:Vancouver Island Technology Park Unit 3204-4464 Markham Street Victoria, British Columbia, V8Z 7X8, Canada
Top Services
Analytical
Analytical Lab Services
Discovery and Preclinical
Chemistry/Discovery Tech./In silico services
API/Biologicals Production
API/Biologics development and manufacturing
- Biologics development and manufacturing
- Antibody/protein/viral vectors/vaccine mfg.
- Vaccine development/manufacturing
Research Supplies
Life Sciences Supplies/Reagents
Bioanalytical
Bioanalytical Assay Services
Canada
- (20.Apr.2022) IPA's Advanced PolyTope TATX-03, a Multi-Antibody Cocktail, Potently Prevents in Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to All Other Variants of Concern
- (14.Apr.2022) IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to Its Antibody Discovery Capabilities and Offerings
- (29.Mar.2022) IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics With Methodology to Encode Omics and Power Drug Development With Advanced Artificial Intelligence
- (16.Mar.2022) ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
- (14.Mar.2022) IPA Selected to Work With Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation Under SBIR Contract From Defense Health Agency Within US Department of Defense
- (09.Mar.2022) IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope TATX-03
- (31.Jan.2022) Immunotherapeutic PolyTope From ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission
- (18.Jan.2022) ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance Its Antibody Research Operations and Environmental Sustainability
- (17.Jan.2022) ImmunoPrecise Antibodies Announces Grant of Stock Options
- (03.Jan.2022) ImmunoPrecise Antibodies Announces Grant of Stock Options
- (20.Dec.2021) ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope TATX-03 Antibody Cocktail Manufacturing Collaboration
- (13.Dec.2021) ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
- (30.Nov.2021) ImmunoPrecise Update on Its SARS-CoV-2 PolyTope Multi-Antibody Cocktail Development Program
- (13.Oct.2021) ImmunoPrecise Announces At-The-Market Facility of Up to US$50 Million
- (07.Oct.2021) Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
- (09.Sep.2021) ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
- (08.Sep.2021) ImmunoPrecise's Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
- (28.Jul.2021) ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
- (22.Jul.2021) ImmunoPrecise's PolyTope TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in Vitro Pseudovirus Assays